Our newest portfolio stocks pulled back from their recent 52-week high, so we're buying more
We are buying 300 shares of Bristol-Myers Squibb at approximately $58 each. Following Wednesday's trade, Jim Cramer's Charitable Trust will…
We are buying 300 shares of Bristol-Myers Squibb at approximately $58 each. Following Wednesday's trade, Jim Cramer's Charitable Trust will…
The new trial data has cemented Club's lead position behind Eli Lilly in the highly competitive anti-obesity drug race. Eli…
We are purchasing 25 shares of Danaher at approximately $229 each. Following Monday's trade, Jim Cramer's Charitable Trust will own…
My Top 10 Things to Watch for Friday, Nov. 15 1. President-elect Donald Trump's decision to nominate prominent vaccine skeptic…
Enthusiasm for Eli Lilly, the club's holding company, needs to be tempered, at least for now, as Wall Street grapples…
GE Healthcare reported a mixed quarter before Wednesday's opening bell. While revenue declined slightly, an improvement in earnings along with…
Shares of Abbott Laboratories rose on Friday after the Club holding company scored a surprise victory in a trial into…
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Danaher shares fell on Tuesday even though the life sciences company regained growth in its key bioprocessing business in the…
Medical device maker Abbott Laboratories on Wednesday delivered better-than-expected quarterly results and raised its profit forecasts for the third consecutive…